Stay updated on Apremilast-Dupilumab Combo in Eczema Clinical Trial
Sign up to get notified when there's something new on the Apremilast-Dupilumab Combo in Eczema Clinical Trial page.

Latest updates to the Apremilast-Dupilumab Combo in Eczema Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedPage revision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check23 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check52 days agoChange DetectedThe page now displays Revision: v3.4.2. The funding-status notice has been removed (the previous Revision: v3.4.1 was deleted).SummaryDifference0.5%

- Check59 days agoChange DetectedAdded a funding-status notice at the top of the page about potential data currency issues and a Revision banner showing v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check66 days agoChange DetectedAdded a glossary display option and updated labeling for QC-related items (Last Update Submitted that Met QC Criteria; No FEAR Act Data) with a revision notice (Revision: v3.4.0), replacing the previous variants (Last Update Submitted that met QC Criteria; No FEAR Act data; Revision: v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check80 days agoChange DetectedRevision metadata updated from v3.3.3 to v3.3.4 in the page footer. No changes to the study content are apparent.SummaryDifference0.1%

Stay in the know with updates to Apremilast-Dupilumab Combo in Eczema Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Apremilast-Dupilumab Combo in Eczema Clinical Trial page.